Larry Z. Shen - Concepedia

Author

Larry Z. Shen

Amplyx Pharmaceuticals (United States)

Also Known As

L Shen, L. Shen, L. Z. Shen, Larry Shen, Larry Z. Shen, Larry Zaiqian Shen

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Amplyx Pharmaceuticals (United States)Procter & Gamble (United States)Eli Lilly (United States)Henry Ford Hospital Baylor University Medical Center

About

Larry Z. Shen is an author at Amplyx Pharmaceuticals (United States) specializing in statistics, medicine, and statistical inference.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	332
2	Biostatistics	4	4	653
3	Engineering	3	3	213
4	Public Health	3	3	464
5	Diabetes	1	1	63

Larry Z. Shen

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus Orville Kolterman, Dennis Dong Hwan Kim, Larry Z. Shen, American Journal of Health-System Pharmacy	2005	434
Continual Reassessment Method: A Likelihood Approach John O’Quigley, Larry Z. Shen Biometrics Refinement TechniqueBayesian StatisticsBayesian MethodologyBayesian StatisticUncertainty Quantification	1996	369
Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes Mark Fineman, Thomas A. Bicsak, Larry Z. Shen, Diabetes Care	2003	355
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks John B. Buse, Daniel J. Drucker, Kristin Taylor, Diabetes Care	2010	347
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial Robert E. Ratner, Richard A. Dickey, Mark Fineman, Diabetic Medicine	2004	303
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes Priscilla Hollander, Philip T. Levy, Mark Fineman, Diabetes Care	2003	299
A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes Fred W. Whitehouse, Davida Kruger, Mark Fineman, Diabetes Care	2002	258
Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes Mark Fineman, Larry Z. Shen, Kristin Taylor, Diabetes/Metabolism Research and Reviews	2004	226
Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients Priscilla Hollander, David Maggs, James A. Ruggles, Obesity Research	2004	192
Consistency of continual reassessment method under model misspecification Larry Z. Shen Biometrika Refinement TechniqueData ConsistencyEngineeringUncertainty QuantificationVerification	1996	162

Page 1